Previous close | 0.1771 |
Open | 0.1432 |
Bid | 0.0000 x N/A |
Ask | 0.0000 x N/A |
Day's range | 0.1432 - 0.1432 |
52-week range | 0.1432 - 0.1432 |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | -0.12 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
BAGNEUX, France, May 23, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV – the "Company"), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, informs its shareholders that the Extraordinary Shareholders’ Meeting held today was able to validly deliberate.
BAGNEUX, France, May 20, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV – the "Company"), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announced the signing of an addendum to the contract signed with Winance on April 11, 2022 for the purpose of implementing a new financing line providing for the provision, subject to the prior approval of the Shareholders’ Meeting of May 23, 2022 and the conditions for dr
BAGNEUX, France, May 05, 2022--Regulatory News: Genomic Vision (FR0011799907 – GV – the "Company") (Paris:GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today reported its revenue for the first quarter and its cash position at March 31, 2022.